Bessemer Group
CYTK icon

Bessemer Group’s Cytokinetics CYTK Stock Holding History

Bessemer Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$168K Sell
1,973
-995
-34% -$71.4K ﹤0.01% 1428
2026
Q1 		$196K Sell
2,968
-39
-1% -$2.48K ﹤0.01% 1400
2025
Q4 		$191K Buy
3,007
+427
+17% +$26.6K ﹤0.01% 1360
2025
Q3 		$141K Buy
2,580
+2,063
+399% +$85K ﹤0.01% 1208
2025
Q2 		$17K Sell
517
-41
-7% -$1.43K ﹤0.01% 1613
2025
Q1 		$23K Buy
558
+7
+1% +$322 ﹤0.01% 1493
2024
Q4 		$26K Sell
551
-1,381
-71% -$71.7K ﹤0.01% 1435
2024
Q3 		$102K Buy
1,932
+716
+59% +$39.9K ﹤0.01% 1280
2024
Q2 		$66K Sell
1,216
-44
-3% -$2.66K ﹤0.01% 1233
2024
Q1 		$88K Buy
1,260
+1,255
+25,100% +$97.1K ﹤0.01% 1198
2023
Q4 		$0 Hold
5
– – ﹤0.01% 2172
2023
Q3 		$0 Sell
5
-73
-94% -$2.43K ﹤0.01% 2195
2023
Q2 		$3K Buy
+78
New +$2.89K ﹤0.01% 1933
2020
Q2 		– Sell
-2,900
Closed -$34K – 1708
2020
Q1 		$34K Buy
+2,900
New +$37K ﹤0.01% 1275
2016
Q1 		– Sell
-207
Closed -$2K – 1509
2015
Q4 		$2K Buy
+207
New +$2.03K ﹤0.01% 1497

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bessemer Group's CYTK Position: Q2 2026 in Review

Bessemer Group reduced its Cytokinetics (CYTK) stake by 34% in Q2 2026, selling an estimated $71.4K and leaving 1,973 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #1428.

Bessemer Group first reported a position in CYTK in Q4 2015 and has held it in 15 quarters since. The position peaked at $196K in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Bessemer Group held 1,973 shares of Cytokinetics worth $168K as of Q2 2026.
  • Bessemer Group sold 995 Cytokinetics shares in Q2 2026, an estimated $71.4K.
  • Cytokinetics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1428 holding.
  • Bessemer Group first reported a position in Cytokinetics in Q4 2015 and has held it in 15 quarters since.
  • Bessemer Group's Cytokinetics position peaked at $196K in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.